Chimeric antigen receptor T-cell therapy for solid tumors
about
Targeted calcium influx boosts cytotoxic T lymphocyte function in the tumour microenvironment.Emerging immunotherapeutics in adenocarcinomas: A focus on CAR-T cellsThe Role of the Tumor Vasculature in the Host Immune Response: Implications for Therapeutic Strategies Targeting the Tumor Microenvironment.CAR-T cell therapy in gastrointestinal tumors and hepatic carcinoma: From bench to bedside.Regional Delivery of Chimeric Antigen Receptor (CAR) T-Cells for Cancer Therapy.Clonal cooperativity in heterogenous cancers.Current challenges for the targeted delivery and molecular imaging of stem cells in animal models.Tumor-targeting domains for chimeric antigen receptor T cells.Concise Review: An (Im)Penetrable Shield: How the Tumor Microenvironment Protects Cancer Stem Cells.Current status and perspectives of chimeric antigen receptor modified T cells for cancer treatment.Biomarkers and therapeutic advances in glioblastoma multiforme.Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia.Inducible Activation of MyD88 and CD40 in CAR T Cells Results in Controllable and Potent Antitumor Activity in Preclinical Solid Tumor Models.Computational study on the origin of the cancer immunotherapeutic potential of B and T cell epitope peptides.Next frontiers in CAR T-cell therapy.Human CD26high T cells elicit tumor immunity against multiple malignancies via enhanced migration and persistence.Prospects for combined use of oncolytic viruses and CAR T-cells.Study protocol for THINK: a multinational open-label phase I study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumour types.Long-term persistence and function of hematopoietic stem cell-derived chimeric antigen receptor T cells in a nonhuman primate model of HIV/AIDS.Immunotherapy for brain tumors: understanding early successes and limitations.Advances in immunotherapeutic research for glioma therapy.Cell Membrane Bioconjugation and Membrane-Derived Nanomaterials for Immunotherapy.Foxp3 Reprograms T Cell Metabolism to Function in Low-Glucose, High-Lactate Environments.Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: lessons learned and strategies for moving forward.Multifunctional nanoparticles for cancer immunotherapy: A groundbreaking approach for reprogramming malfunctioned tumor environment.Development of anti-human mesothelin-targeted chimeric antigen receptor (CAR) messenger RNA (mRNA)-transfected peripheral blood lymphocytes (CARMA-hMeso) for ovarian cancer therapy.The challenges of solid tumor for designer CAR-T therapies: a 25-year perspective.Genetic abrogation of immune checkpoints in antigen-specific cytotoxic T-lymphocyte as a potential alternative to blockade immunotherapy.Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses.Chimeric antigen receptors: unleashing a new age of anti-cancer therapy
P2860
Q33715943-DA6C50DF-C676-4573-8933-3387DD0DDB7DQ33833475-A1BBD70A-A81B-4191-9C5C-0922BC99C242Q37516448-364D1B03-C19A-4F66-A1C6-9BF1EDA5112FQ37559401-66C14222-9D43-4D9F-8118-DC46058DDFC8Q38656009-83EDF5DA-7B7B-40CF-8C2E-8F2B11B2AC32Q38943125-4D62FA58-FDA0-4983-B3EE-40F0AA24E7C8Q38998703-F9909C52-9C6D-4D08-8416-137D0509966AQ39045535-8F0592C3-CBEA-4735-80D0-535DC4D99B60Q39138664-68F452A8-E33F-4707-A8EE-DE11B53DCDF3Q39280002-3CAA91AC-248B-45EB-92E4-A1F801DBFD4FQ40070524-21EAAB4B-4DC8-46A0-9E00-31072E7D6DA1Q40314122-B399BB71-1E18-485F-805E-F8A0C19C8F6EQ45870666-A30DD3C8-D1C8-4718-BC79-93D615B6418CQ45945817-98FB2632-8045-4D2F-B34B-5826DAE32D14Q46848787-68901E91-C8F9-4E42-9EA3-F883F1395BF3Q47094002-DD709296-049F-41BB-88F1-16FF2E793B72Q47103891-0D24B6C0-9FE3-4210-822D-7EB1D5640ACCQ47159409-E0C5539F-B66B-450E-8BD3-915229975651Q47172279-C21A8DCD-82DC-4F4F-91B8-4EF3CE3A8F08Q47555498-C8CDEC10-7738-4C11-890D-7F24FC13D344Q47569046-772D5DF5-B558-4BEB-AA67-68C1E9227152Q47738496-721174A0-39E1-41D8-8DF7-2E22AD6BBDF8Q47914208-A6C19530-C6F8-4122-8FE5-2C1EAD8967AEQ49280922-F8BD8C0E-9C45-4F45-B511-0C0B272E1F78Q49391681-19778289-35F8-46AD-AC34-ED08928E4276Q50025535-C91D1D5B-CA3F-4137-8E8F-310E2DC12586Q50033731-C81326FA-22AC-4253-A257-94FB29ACFBEDQ52431278-5EE19927-C3E3-4392-B8F2-E423ED023C1FQ54965295-8867ED3E-BD11-4D01-A0D4-2EDA4B1494B6Q59126606-EDDCE0AA-C9D4-41AB-BE2A-51A11BAFB5B7
P2860
Chimeric antigen receptor T-cell therapy for solid tumors
description
2016 nî lūn-bûn
@nan
2016 թուականին հրատարակուած գիտական յօդուած
@hyw
2016 թվականին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Chimeric antigen receptor T-cell therapy for solid tumors
@ast
Chimeric antigen receptor T-cell therapy for solid tumors
@en
Chimeric antigen receptor T-cell therapy for solid tumors
@nl
type
label
Chimeric antigen receptor T-cell therapy for solid tumors
@ast
Chimeric antigen receptor T-cell therapy for solid tumors
@en
Chimeric antigen receptor T-cell therapy for solid tumors
@nl
prefLabel
Chimeric antigen receptor T-cell therapy for solid tumors
@ast
Chimeric antigen receptor T-cell therapy for solid tumors
@en
Chimeric antigen receptor T-cell therapy for solid tumors
@nl
P2093
P2860
P3181
P356
P1476
Chimeric antigen receptor T-cell therapy for solid tumors
@en
P2093
Edmund Moon
Kheng Newick
Steven M Albelda
P2860
P3181
P356
10.1038/MTO.2016.6
P407
P577
2016-01-01T00:00:00Z